Filtered By:
Drug: Rituxan

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 306 results found since Jan 2013.

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity)
Conclusions Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatmen...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome
This study was carried out after written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Stanford University and UCLA Institutional Review Boards. Author Contributions MB provided patient care and obtained IRB approval. RO prepared histology images. MB, TT, and RB designed the research. TT and LP conducted experiments and analyzed data. MB made the molecular model. MB and TT wrote the manuscript. Funding Funding for this work came from the Jeffrey Modell Foundation and from the NIH/NIGMS (R01 GM110482 to MB)....
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children
Nicolaas G. van der Maas, Dagmar Berghuis, Mirjam van der Burg and Arjan C. Lankester* Willem-Alexander Children's Hospital, Department of Pediatrics and Laboratory for Pediatric Immunology, Leiden University Medical Center, Leiden, Netherlands B cell reconstitution after hematopoietic stem cell transplantation (HSCT) is variable and influenced by different patient, donor, and treatment related factors. In this review we describe B cell reconstitution after pediatric allogeneic HST, including the kinetics of reconstitution of the different B cell subsets and the development of the B cell repertoire, and d...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - April 9, 2019 Category: Allergy & Immunology Source Type: research

Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
Conclusions The sheer number of factors to consider when translating observations between macaques and humans makes the process a challenging, multidimensional one. Differences in the structures and activities of IgG subclasses, and polymorphisms in protein sequence and post-translational modification of antibody receptors are a subset of the many relevant considerations. Copy number variation, splice variants, and alleles with sequence variation outside of coding regions have been associated with a diversity of phenotypes in humans (183, 213–217), and are presumed to exist in NHP. A number of differences in the p...
Source: Frontiers in Immunology - April 7, 2019 Category: Allergy & Immunology Source Type: research

Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Chronic Fatigue Syndrome Does Not Improve With Rituximab Chronic Fatigue Syndrome Does Not Improve With Rituximab
Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) do not improve following B-lymphocyte depletion with rituximab, according to results from the RituxME randomized controlled trial.Reuters Health Information
Source: Medscape Allergy Headlines - April 3, 2019 Category: Allergy & Immunology Tags: Internal Medicine News Source Type: news

"Rituximab hypersensitivity and desensitization: A personalized approach to treat cancer and connective tissue diseases".
PMID: 30885801 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - March 14, 2019 Category: Allergy & Immunology Authors: Yang BC, Castells MC Tags: Ann Allergy Asthma Immunol Source Type: research

“Rituximab hypersensitivity and desensitization: A personalized approach to treat cancer and connective tissue diseases”
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis, and vasculitis)1. Hypersensitivity reactions to rituximab can range from type I IgE-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis), to cytokine-mediated reaction (fevers, chills, rigors), or a mix of both, thus limiting the use of rituximab as first line therapy for many cases. Desensitization is a new therapeutic approach which can be performed with rituximab to offset these reactions.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2019 Category: Allergy & Immunology Authors: Barbara C. Yang, Mariana C. Castells Tags: Challenging Clinical Cases Source Type: research

Rituximab hypersensitivity and desensitization
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis and vasculitis).1 Hypersensitivity reactions to rituximab can range from type I immunoglobulin E (IgE)-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis) to cytokine-mediated reaction (fevers, chills, rigors) or a mix of both, thus limiting the use of rituximab as first-line therapy for many cases. Desensitization is a new therapeutic approach that can be performed with rituximab to offset these reactions.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2019 Category: Allergy & Immunology Authors: Barbara C. Yang, Mariana C. Castells Tags: Challenging Clinical Cases Source Type: research

Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency
ConclusionsAutoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should prompt further evaluation. Multi-lineage cytopenias are often refractory to immunosuppressive treatment and may require hematopoietic cell transplantation for definitive management.
Source: The Journal of Allergy and Clinical Immunology: In Practice - March 14, 2019 Category: Allergy & Immunology Source Type: research

Rituximab Use and Immunological Monitoring in Pediatric Patients
Rituximab is an anti-CD20 monoclonal antibody used in both pediatric and adult patients. Despite its widespread use, immunologic monitoring has not been consistent among subspecialties.
Source: Journal of Allergy and Clinical Immunology - February 1, 2019 Category: Allergy & Immunology Authors: Sara Barmettler, MeiSing Ong, Jocelyn R. Farmer, Jolan E. Walter Source Type: research

Secondary Hypogammaglobulinemia
This article reviews immunosuppressive medications, including biological treatments that cause secondary hypogammaglobulinemia. It summarizes risk factors for rituximab-induced hypogammaglobulinemia, such as preexisting low immunoglobulin G levels, CD19 levels, host factors, and additive effect of all immunomodulatory drugs used. The evaluation and management of secondary hypogammaglobulinemia are discussed.
Source: Immunology and Allergy Clinics of North America - November 20, 2018 Category: Allergy & Immunology Authors: Blanka Kaplan, Vincent R. Bonagura Source Type: research

Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab
Patients being considered for rituximab therapy should be screened for hypogammaglobulinemia before and after rituximab administration, researchers report.Reuters Health Information
Source: Medscape Allergy Headlines - November 8, 2018 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news